• We designed SSOs that block APP exon splicing and induce

  2024-08-01

  

  We designed SSOs that block APP exon 17 splicing and induce the production of an alternatively spliced APP mRNA lacking exon 17 (APPΔex17). APPΔex17 mRNA encodes an APP protein isoform that lacks 49 oxytocin antagonist including the γ-secretase cleavage sites that give rise to the toxic, AD-associa

• br Results br Discussion Cardiac dysfunction common complica

  2024-08-01

  

  Results Discussion Cardiac dysfunction, common complication of severe sepsis, is one cause of death in intensive care units. Accumulated evidence revealed the regulatory effect of autophagy on sepsis-induced cardiac dysfunction [15], [22], although the mechanisms in young and aging are not elu

• Since the publication of the guidelines data

  2024-08-01

  

  Since the publication of the 2011 guidelines, data have continued to accumulate indicating that the cognitive decline in AD occurs continuously over a long period [6–8], and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]. Thus, the disease is n

• Blocking the action of CREB with

  2024-08-01

  

  Blocking the action of CREB with the C646 inhibitor together with increasing Akt activation with the SC79 agonist is particularly interesting as it significantly reduced wound closure time from 7 days (which is required for complete closure of control hTECs exposed to DMSO) to only 4 days (when hTEC

• Aminoallyl-UTP sale br Experimental section br Results and d

  2024-08-01

  

  Experimental section Results and discussion Conclusions We present a simple, sensitive and selective assay of ADA activity and its inhibitor using the enzyme catalyzed reaction and the different interaction intensity of dye-labeled AD aptamer, aptamer/AD complex with GO. The as-proposed met

• The first rationally designed dual mPGES LO

  2024-07-31

  

  The first rationally designed dual mPGES-1/5-LO inhibitor was reported in 2008 and represents a structural derivative of pirinixic Anisomycin - a synthetic agonist of PPARα with lipid-lowering properties (Koeberle et al., 2008b). Further α-alkyl- and α-aryl-substituted derivatives have been synthes

• In addition to the data provided by the Ki

  2024-07-31

  

  In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr

• In this report the natural compound deguelin potently and

  2024-07-31

  

  In this report, the natural compound deguelin potently and dose-dependently suppressed Aurora B kinase activity in vitro, indicating that this compound is an effective Aurora B inhibitor. The docking study indicated that deguelin was docked into the ATP-binding pocket of Aurora B and formed hydroph

• Matthew et al synthesized and carried out SAR studies of

  2024-07-31

  

  Matthew et al. synthesized and carried out SAR studies of imidazo-[1,2-a]-pyrazine as Aurora kinase inhibitors with enhanced kinase selectivity and found that L-NMMA citrate 39 showed optimal potency on Aurora-A and Aurora-B with IC50 value of 4 nM and 13 nM while on phosphorylation histone H3 (pHH3

• Lower LDL C mediated by variants in the

  2024-07-31

  

  Lower LDL-C mediated by variants in the ACL gene is causally associated with the risk of cardiovascular events. Because, genetic variants that mimic the effect of an ACL inhibitor have the same effect on the risk of cardiovascular events per unit change in LDL-C as variants that mimic the effect of

• As shown in B the recombinant human

  2024-07-31

  

  As shown in B, the recombinant human 15-LOX-1 (30nM) showed a time-dependent increase in fluorescent signal, and signal development was almost completed within 20min in the presence of 50μM arachidonic mecamylamine sale and 5μM DHR. For both purified enzyme and cell lysates, the enzyme activities di

• br Author contributions br Acknowledgments TJC

  2024-07-31

  

  Author contributions Acknowledgments TJC, KW, and VG are supported by awards made to MJN: a Consolidator Grant from the European Research Council under Grant no. 311336; a University Research Fellowship from the Royal Society, and a Career Development Award from the Human Frontiers Science Pro

• br Drugs with documented pro apoptotic effects on

  2024-07-31

  

  Drugs with documented pro-apoptotic effects on platelets More than 200 drugs are reported to cause thrombocytopenia [5,42]. The concept of platelet apoptosis is relatively new and was only recently evaluated in the context of drug-induced thrombocytopenia [43]. Table 2 lists the drugs presently k

• The contractility index showed positive inotropic effects of

  2024-07-31

  

  The contractility index showed positive inotropic effects of apelin in both doses at min 5 (Fig. 3, Fig. 5). Although the mean arterial pressure did not recover to the baseline, the contractility index increased, the relaxation index (tau) and ±dp/dt max returned back to their baseline, and left ven

• Finally the comparison between data

  2024-07-31

  

  Finally, the comparison between data obtained by antioxidant assays in in vitro cultured cells [11], [12] and in liposomes has disclosed the possibility to choose more confidently “the better phenolipid” of a series of fatty acids esters antioxidant derivatives. Looking at the physical parameters th

15346 records 113/1024 page Previous Next First page 上5页 111112113114115 下5页 Last page